ReviewMolecular neurobiology2026
Quercetin-Based Nanotherapeutics for Targeted Drug Delivery in Alzheimer's Disease: Comparative Insights into Molecular Mechanisms, Blood-Brain Barrier Targeting and Therapeutic Perspectives.
Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder driven by interconnected pathological processes, including amyloid-β (Aβ) accumulation, tau hyperphosphorylation, oxidative stress, mitochondrial dysfunction, cholinergic impairment, and chronic neuroinflammation. Quercetin, a naturally occurring flavonoid, exhibits pleiotropic neuroprotective activities by modulating oxidative stress, inflammatory signaling, pathological protein aggregation, mitochondrial function, and cholinergic pathways. However, poor aqueous solubility, rapid metabolism, limited systemic bioavailability, and restricted brain exposure constrain its therapeutic translation. Nanotechnology-based drug delivery approaches have therefore been explored to improve quercetin's physicochemical and pharmacokinetic properties and facilitate brain delivery. This review critically evaluates recent advances in quercetin-loaded polymeric nanoparticles, lipid-based nanocarriers, liposomes, inorganic systems, and biomimetic nanocarriers for AD. Particular emphasis is placed on the association between nanocarrier composition and drug-loading capacity, release behavior, stability, route of administration, and brain delivery. The review discusses BBB-targeting approaches, including receptor-mediated and adsorptive-mediated transport, alongside targeted drug-delivery strategies and the underlying molecular pathways, with particular attention to the distinction between evidence for BBB transport and actual brain exposure. The review further compares therapeutic outcomes across cellular, transgenic AD models, biodistribution, translational barriers, and regulatory considerations. Collectively, this review provides a mechanistic and comparative perspective on the potential and limitations of nanotechnology-enabled quercetin delivery and identifies priorities for developing clinically translatable nanotherapeutic strategies for AD.
Indexed as
Identifiers
42749965What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.